Pricing Log in Create free account

Palvella Therapeutics, Inc. (PVLA) vs Urogen Pharma (URGN)

Palvella Therapeutics, Inc. and Urogen Pharma are both Biotechnology companies. Palvella Therapeutics, Inc. and Urogen Pharma are of similar size ($1.8B and $1.8B). Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 146.7% against 100.3%. Palvella Therapeutics, Inc. has the higher net margin (0.00% vs −51.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Palvella Therapeutics, Inc. leads on 10 and Urogen Pharma on 6.

Valuation

Metric PVLA URGN Biotechnology median
P/E n/m n/m 8.50
P/S 41.55 9.23 9.71
P/B 7.96 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 35.55 9.66 9.21
Earnings yield (4.01%) (5.73%) (33.15%)
Free cash flow yield (1.86%) (9.14%) (25.50%)

Profitability

Metric PVLA URGN Biotechnology median
Gross margin 100.00% 90.85% 65.16%
Operating margin 0.00% (35.32%) 0.00%
Net margin 0.00% (51.73%) 0.00%
Free cash flow margin 0.00% (84.32%) 0.00%
Return on equity (46.63%) 86.49% (56.36%)
Return on assets (37.70%) (42.33%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PVLA URGN Biotechnology median
Revenue growth (TTM) 146.67% 100.27% 6.02%
EPS growth (last fiscal year) 52.62% (7.77%) 30.26%
Revenue growth, 5-year CAGR 8.03% 56.22% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PVLA URGN Biotechnology median
Debt to equity 0.00 (1.45) 0.00
Current ratio 21.18 3.80 4.72
Net debt to EBITDA 1.50 0.00 0.96

Dividend

Metric PVLA URGN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric PVLA URGN Biotechnology median
Market cap 1.83b 1.79b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack